You just read:

Santaris Pharma A/S to Report New Clinical Data From Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting

News provided by

Santaris Pharma A/S

Oct 03, 2011, 07:15 ET